Page 35 - Read Online

Laubach et al. Cancer Drug Resist 2023;6:611-41 https://dx.doi.org/10.20517/cdr.2023.60 Page 637

134. Kim RH, Coates JM, Bowles TL, et al. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-
independent apoptosis. Cancer Res 2009;69:700-8. DOI PubMed PMC
135. Kremer JC, Prudner BC, Lange SES, et al. Arginine deprivation inhibits the warburg effect and upregulates glutamine anaplerosis and
serine biosynthesis in ASS1-Deficient cancers. Cell Rep 2017;18:991-1004. DOI PubMed PMC
136. Wang W, Zou W. Amino acids and their transporters in T Cell immunity and cancer therapy. Mol Cell 2020;80:384-95. DOI
PubMed PMC
137. Crump NT, Hadjinicolaou AV, Xia M, et al. Chromatin accessibility governs the differential response of cancer and T cells to
arginine starvation. Cell Rep 2021;35:109101. DOI PubMed PMC
138. Gannon PO, Godin-Ethier J, Hassler M, et al. Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human
prostate cancer. PLoS One 2010;5:e12107. DOI PubMed PMC
139. Tate DJ Jr, Vonderhaar DJ, Caldas YA, et al. Effect of arginase II on L-arginine depletion and cell growth in murine cell lines of
renal cell carcinoma. J Hematol Oncol 2008;1:14. DOI PubMed PMC
140. Porembska Z, Luboiński G, Chrzanowska A, Mielczarek M, Magnuska J, Barańczyk-Kuźma A. Arginase in patients with breast
cancer. Clin Chim Acta 2003;328:105-11. DOI PubMed
141. Chen C, Jiang X, Zhao Z. Inhibition or promotion, the potential role of arginine metabolism in immunotherapy for colorectal cancer.
All Life 2023;16:2163306. DOI
142. Rodriguez PC, Quiceno DG, Zabaleta J, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits
T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004;64:5839-49. DOI
+
143. Norian LA, Rodriguez PC, O’Mara LA, et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8 T cell function via -arginine
L
metabolism. Cancer Res 2009;69:3086-94. DOI PubMed PMC
144. Ino Y, Yamazaki-Itoh R, Oguro S, et al. Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts
poor outcome in patients with pancreatic cancer. PLoS One 2013;8:e55146. DOI PubMed PMC
145. Sippel TR, White J, Nag K, et al. Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular
immune function by targeting arginase I. Clin Cancer Res 2011;17:6992-7002. DOI
146. Ren W, Zhang X, Li W, et al. Circulating and tumor-infiltrating arginase 1-expressing cells in gastric adenocarcinoma patients were
mainly immature and monocytic Myeloid-derived suppressor cells. Sci Rep 2020;10:8056. DOI PubMed PMC
147. Lowe MM, Boothby I, Clancy S, et al. Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues. JCI Insight
2019;4:129756. DOI PubMed PMC
148. Gunji Y, Hori S, Aoe T, et al. High frequency of cancer patients with abnormal assembly of the T cell receptor-CD3 complex in
peripheral blood T lymphocytes. Jpn J Cancer Res 1994;85:1189-92. DOI PubMed PMC
149. Zea AH, Rodriguez PC, Culotta KS, et al. -Arginine modulates CD3ζ expression and T cell function in activated human T
L
lymphocytes. Cell Immunol 2004;232:21-31. DOI PubMed
150. Sosnowska A, Chlebowska-Tuz J, Matryba P, et al. Inhibition of arginase modulates T-cell response in the tumor microenvironment
of lung carcinoma. Oncoimmunology 2021;10:1956143. DOI PubMed PMC
151. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood
2007;109:1568-73. DOI PubMed PMC
152. Geiger R, Rieckmann JC, Wolf T, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell
2016;167:829-42.e13. DOI PubMed PMC
153. Czystowska-Kuzmicz M, Sosnowska A, Nowis D, et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses
and promote tumor growth in ovarian carcinoma. Nat Commun 2019;10:3000. DOI PubMed PMC
154. Munder M, Engelhardt M, Knies D, et al. Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion.
PLoS One 2013;8:e63521. DOI PubMed PMC
155. Mussai F, Wheat R, Sarrou E, et al. Targeting the arginine metabolic brake enhances immunotherapy for leukaemia. Int J Cancer
2019;145:2201-8. DOI PubMed PMC
156. Aaboe Jørgensen M, Ugel S, Linder Hübbe M, et al. Arginase 1-based immune modulatory vaccines induce anticancer immunity and
synergize with anti-PD-1 checkpoint blockade. Cancer Immunol Res 2021;9:1316-26. DOI PubMed
157. Satoh Y, Kotani H, Iida Y, Taniura T, Notsu Y, Harada M. Supplementation of l-arginine boosts the therapeutic efficacy of anticancer
chemoimmunotherapy. Cancer Sci 2020;111:2248-58. DOI PubMed PMC
158. He X, Lin H, Yuan L, Li B. Combination therapy with L-arginine and α-PD-L1 antibody boosts immune response against
osteosarcoma in immunocompetent mice. Cancer Biol Ther 2017;18:94-100. DOI PubMed PMC
159. Canale FP, Basso C, Antonini G, et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature
2021;598:662-6. DOI
160. Grzybowski MM, Stańczak PS, Pomper P, et al. OATD-02 validates the benefits of pharmacological inhibition of arginase 1 and 2 in
cancer. Cancers 2022;14:3967. DOI PubMed PMC
161. Borek B, Nowicka J, Gzik A, et al. Arginase 1/2 inhibitor OATD-02: From discovery to first-in-man setup in cancer immunotherapy.
Mol Cancer Ther 2023;22:807-17. DOI
162. Pilanc P, Wojnicki K, Roura AJ, et al. A novel oral arginase 1/2 inhibitor enhances the antitumor effect of PD-1 inhibition in murine
experimental gliomas by altering the immunosuppressive environment. Front Oncol 2021;11:703465. DOI PubMed PMC
163. Naing A, Bauer T, Papadopoulos K, et al. Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with